LETC
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies[1].
Product Specifications
CAS Number
951131-13-8
UNSPSC
12352005
Target
α-synuclein
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/letc.html
Purity
98.30
Smiles
CCN(CC)C1=CC=C2C(SC3=C(N2)C=CC(N(CC)CC)=C3)=C1.Cl.Cl
Molecular Formula
C20H29Cl2N3S
Molecular Weight
414.44
References & Citations
[1]Karima Schwab, et al. LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy. Eur J Pharmacol. 2024 May 5:970:176505.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
α-synuclein Aggregation
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RC205220L2V 200 µL
DUSP1 (NM_004417) Human Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details